ClinicalTrials.gg

Program

PIPE-791

A development code. Also written as “PIPE-791 Dose A” and “PIPE-791 Dose B”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Chronic Pain · Multiple Sclerosis, led by Contineum Therapeutics.

Furthest: phase 2, since Dec 8, 20254 company-led studies, 1 open or runningNext primary completion: May 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Contineum Therapeutics41 open or runningphase 2since Dec 8, 2025Jul 19, 2023May 2028phase 2 · NCT07284459

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2023First study: phase 1 study in Multiple SclerosisFirst studyNCT05983939 · 56 enrolled · United States
  2. Nov 6, 2024Phase 1 study in Idiopathic Pulmonary FibrosisNCT06683612 · 16 enrolled · United Kingdom
  3. Jan 22, 2025Phase 1 study in Chronic PainNCT06810245 · 43 enrolled · United States
  4. Dec 8, 2025Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07284459 · 324 planned · Argentina, Australia, Belgium and more

Ahead

  1. May 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07284459

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07284459Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more2RecruitingMay 2028324
NCT06810245Chronic Pain · United States1CompletedJan 20, 202643
NCT06683612Idiopathic Pulmonary Fibrosis · United Kingdom1CompletedJun 4, 202516
NCT05983939Multiple Sclerosis · United States1CompletedFeb 1, 202456

How it is read

Names in the registry

  • “PIPE-791”, 3 entries
  • “PIPE-791 Dose A”, 1 entry
  • “PIPE-791 Dose B”, 1 entry

Codes read as this program: PIPE791.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.